CELL DEATH DISCOV 润色咨询

Cell Death Discovery

出版年份:暂无数据 年文章数:928 投稿命中率: 开通期刊会员,数据随心看

出版周期:暂无数据 自引率:暂无数据 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2023-11-08 ms6000000748440029 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:神经系统凋亡及机制
    经验分享:更新一下投稿时间线:
    Manuscript Received: 7.3
    Editor Assigned :7.3
    Manuscript Under Consideration: 7.4
    Manuscript Under Consideration: 8.31
    Decision Made: 9.2
    Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)
    Manuscript Received: 10.18
    Editor Assigned: 10.18
    Manuscript Under Consideration: 10.19
    目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?

    58

    展开58条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-07-08 303367978

    under consideration 已经7天了 还没外审

    48

    展开48条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2023-08-11 风轻云淡23 来自贵州省

    偏重的研究方向:肿瘤转移;蛋白互作机制
    经验分享:投稿小小CDD,情况如下:
    Stage Start Date
    Manuscript Under Consideration 27th Jul 23 05:09:14
    Editor Assigned 25th Jul 23 12:51:55
    Manuscript Received 25th Jul 23 12:51:54
    投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?

    45

    展开45条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-22 lovebanana

    审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0
    偏重的研究方向:机制;肿瘤
    经验分享:7.5号上传,
    8.31 major revise
    11.10 minor revise
    12.21 accept
    先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.
    很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。

    44

    展开44条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-03-22 12362864m67暂无昵称

    请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。

    26

    展开26条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2023-10-29 ms6000001563747786 来自江西省

    偏重的研究方向:细胞死亡
    经验分享:各位大哥 最近这个期刊的效率咋样呀

    25

    展开25条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-09-22 146b8015m10(暂无昵称)

    7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘

    23

    展开23条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-08-03 雨中龙

    我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催

    23

    展开23条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-08-18 科研小白i

    请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?

    22

    展开22条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2167353, encodeId=b340216e35352, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:神经系统凋亡及机制<br>经验分享:更新一下投稿时间线:<br>Manuscript Received: 7.3<br>Editor Assigned :7.3<br>Manuscript Under Consideration: 7.4<br>Manuscript Under Consideration: 8.31<br>Decision Made: 9.2<br>Decision Sent to Author: 9.8 (一审65天,等的急啊;要求11.1前返回)<br>Manuscript Received: 10.18<br>Editor Assigned: 10.18<br>Manuscript Under Consideration: 10.19<br>目前返回20天了,research square状态还是 Submission checks complete,编辑还没有返回审稿人手里,要怎么办呀?要催吗?二审一般多久呀?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=29, replyNumber=58, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daea8237862, createdName=ms6000000748440029, createdTime=Wed Nov 08 10:04:15 CST 2023, time=2023-11-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=997700, encodeId=aaa899e70086, content=under consideration 已经7天了 还没外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=48, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ec24671199, createdName=303367978, createdTime=Thu Jul 08 22:27:03 CST 2021, time=2021-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152333, encodeId=62f1215233354, content=偏重的研究方向:肿瘤转移;蛋白互作机制<br>经验分享:投稿小小CDD,情况如下:<br> Stage Start Date<br>Manuscript Under Consideration 27th Jul 23 05:09:14<br>Editor Assigned 25th Jul 23 12:51:55<br>Manuscript Received 25th Jul 23 12:51:54<br>投稿第三天收到杂志发来的初审通过的邮件,截止今日,一直是under consideration,目前无ZIP压缩包,是不是被拒了?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=45, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f822479867, createdName=风轻云淡23, createdTime=Fri Aug 11 21:01:20 CST 2023, time=2023-08-11, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=1083099, encodeId=081f108309952, content=审稿速度:6.0 | 投稿命中率:50.0 | 版面费用:2090.0<br>偏重的研究方向:机制;肿瘤<br>经验分享:7.5号上传,<br>8.31 major revise<br>11.10 minor revise<br>12.21 accept<br>先收到provisionally accepted邮件,然后上传终版稿,等待两周正式accept,然后缴费,等待编辑部排版校稿和proof.<br>很慢,也很久,着急毕业的不建议。但是每一次催稿编辑回复都很耐心、及时。一审没催,二审催了一次。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=44, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/9883684c50eb4525aa0007900c15ab09/c44d99673a04497daa77b8386586df68.jpg, createdBy=70f62430863, createdName=lovebanana, createdTime=Wed Dec 22 15:39:06 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950067, encodeId=c30b95006eab, content=请问一下大家,一审被建议转投cell death discovery,应该怎么转投?邮件里给的链接用不了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=26, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210411/da80771de7994056b41a9cf7d83c2962/5ab66ed7d0ad45638a7838a3990b1120.jpg, createdBy=97072405099, createdName=12362864m67暂无昵称, createdTime=Mon Mar 22 10:12:48 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2165544, encodeId=3308216554483, content=偏重的研究方向:细胞死亡<br>经验分享:各位大哥 最近这个期刊的效率咋样呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=25, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cf68540126, createdName=ms6000001563747786, createdTime=Sun Oct 29 13:11:22 CST 2023, time=2023-10-29, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1053865, encodeId=7e1b105386582, content=7月31号投稿,9月22号还在Manuscript Under Consideration,这速度真的不算快了,另外我同学也投的这个,连外审邮件都没收到,半个月就1审完了,真的神秘, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5daf5161008, createdName=146b8015m10(暂无昵称), createdTime=Wed Sep 22 17:23:02 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004901, encodeId=5abf10049011b, content=我的文章一审让大修,就是语言的问题,现在把文章返回去都40天了,还在Under consideration中,咱也不敢问,咱也不敢催的,就很尴尬,有人发过邮件催过嘛,我怕被拒稿,到现在只能等着,不敢催, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=23, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=df1d5308328, createdName=雨中龙, createdTime=Tue Aug 03 15:35:12 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009248, encodeId=1c031009248a3, content=请问已经接收的大佬,这篇杂志需要重复3次wb的原始数据吗?还是只需要原图就行了,1次就行啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=22, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210531/5f7cf98bc3ff42f9bdb3c8abf4b519fe/43510175e95b4dddbccc3b11e600cae0.jpg, createdBy=3c742286789, createdName=科研小白i, createdTime=Wed Aug 18 20:38:01 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082302, encodeId=dd6f108230240, content=想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=21, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6535602345, createdName=ms5000000808384752, createdTime=Tue Dec 21 03:22:45 CST 2021, time=2021-12-21, status=1, ipAttribution=)]
    2021-12-21 ms5000000808384752

    想问下大家,字数要求3500严格吗,稍微超出一些比如3800会不会被打回来。如果修改的话,是二审之前修改呢还是等二审结果回来之后改呢

    21

    展开21条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分